Clinical pharmacology

CenExel Clinical Research Acquires ForCare Clinical Research

Retrieved on: 
Wednesday, August 4, 2021

Salt Lake City, Utah, Aug. 04, 2021 (GLOBE NEWSWIRE) -- CenExel Clinical Research, Inc., ( CenExel ) announces the acquisition of ForCare Clinical Research (CenExel FCR), a Tampa-based clinical research organization with Principal Investigators who have more than 40 years of combined research experience.

Key Points: 
  • Salt Lake City, Utah, Aug. 04, 2021 (GLOBE NEWSWIRE) -- CenExel Clinical Research, Inc., ( CenExel ) announces the acquisition of ForCare Clinical Research (CenExel FCR), a Tampa-based clinical research organization with Principal Investigators who have more than 40 years of combined research experience.
  • The many strengths at CenExel FCR align perfectly with CenExels mission to be the leader in therapeutically focused clinical research.
  • CenExel Clinical Research, Inc. was formed in 2018, and since its formation, CenExel has energetically pursued organic growth as well as the acquisitions of state-of-the-art research centers around the U.S.
  • CenExel Clinical Research ( www.Cenexel.com ) provides unparalleled medical and scientific support in the design and execution of clinical trials.

Truveris Appoints Nanette Oddo President and Chief Executive Officer

Retrieved on: 
Wednesday, August 4, 2021

Truveris announced today that Nanette Oddo has been named President and Chief Executive Officer.

Key Points: 
  • Truveris announced today that Nanette Oddo has been named President and Chief Executive Officer.
  • A veteran industry leader, Ms. Oddo previously served as Truveris Chief Strategy Officer, spearheading the Companys strategic vision during a period of consistent innovation and growth.
  • "Truveris uniquely bends the cost curve to improve the accessibility and affordability of prescription medications, one of the critical challenges facing healthcare today," said Oddo.
  • Prior to Truveris, Oddo spent twelve years in various leadership roles at Phreesia, the leading intake and patient engagement software solution.

Fist Assist Devices, LLC Announces Completion of the Non-Significant Risk FACT Trial

Retrieved on: 
Wednesday, August 4, 2021

Fist Assist Devices, LLC, announces completion of the non-significant risk FACT Trial (Fist Assist Clinical Trial).

Key Points: 
  • Fist Assist Devices, LLC, announces completion of the non-significant risk FACT Trial (Fist Assist Clinical Trial).
  • This is a landmark, global trial evaluating the effectiveness of the FA-1 intermittent compression device on pre-surgery, stage 4 chronic renal failure patients.
  • Fist Assist Devices is a privately held company from Silicon Valley, California that has developed the Fist Assist technology over the past 30 years.
  • The Fist Assist FA-1 device is distributed in India via an alliance with Medifocus ( http://medifocusindia.com ) and in the United States via an alliance with AIROS Medical, Inc. ( www.airosmedical.com )
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005188/en/

Aro Biotherapeutics Expands Leadership Team and Plans Move to New Philadelphia Headquarters to Drive Next Phase of Growth

Retrieved on: 
Wednesday, August 4, 2021

Mr. Greenberg most recently served as Chief Business Officer of Aro, while Mr. Staiger and Dr. Tortorici are new additions to the leadership team.

Key Points: 
  • Mr. Greenberg most recently served as Chief Business Officer of Aro, while Mr. Staiger and Dr. Tortorici are new additions to the leadership team.
  • The Company also announced plans to move its headquarters to The Curtis in Philadelphia to accommodate ongoing growth of its operations and staff.
  • In his expanded role, Scott and his team will help us build additional business capabilities that will support our future growth.
  • Mr. Greenberg joined Aro in 2019 from Roivant Sciences, where he most recently served as Vice President, Head of Operations.

AscellaHealth and Appro-Rx Partner to Provide Specialty Pharmacy Services for Improved Patient Outcomes and Lower Payer Costs

Retrieved on: 
Tuesday, August 3, 2021

Dea Belazi, president and CEO, AscellaHealth, says, “This exciting partnership will support advances in specialty medication compliance and foster a high level of plan member satisfaction -- while helping payers rein in the staggering costs of specialty drugs.”

Key Points: 
  • AscellaHealth , a global specialty pharmacy and healthcare solutions company, today announces a partnership with Appro-Rx , a national prescription benefit management company, to become its specialty pharmacy services and solutions provider.
  • Specialty drugs are vastly more expensive than their traditional drug counterparts, and this partnership not only enables our clients to realize significant cost savings but also to improve health outcomes for their employees.
  • AscellaHealths innovative specialty pharmacy and infusion services provide cost-saving discounts on prescription medications with timely access to therapies, data-driven reporting and patient support programsall of which help to improve patient adherence and health outcomes, thereby optimizing the patient journey.
  • AscellaHealth is a global Specialty Pharmacy and Healthcare services organization serving payers, providers, life sciences and patients, offering a comprehensive portfolio of customized, tech-enabled specialty pharmaceutical and medical management services.

Strategikon Enhances Clinical Trial Planning and Outsourcing. Speeds Time-to-Market.

Retrieved on: 
Tuesday, August 3, 2021

Biopharmaceutical sponsors have several options for budget or scenario development with Clinical Maestro .

Key Points: 
  • Biopharmaceutical sponsors have several options for budget or scenario development with Clinical Maestro .
  • Clinical Maestro's database already supports over 800 standardized tasks, however, sponsors also need to create customized tasks for specific trials.
  • Clinical Maestro equips all participants in clinical trials, Sponsor Companies, Vendors and Service Providers, to budget, source and manage - faster, more accurately, and with less effort.
  • Get the power to model and plan studies and efficiently manage your clinical contracts systematically for faster time to market.

CymaBay Announces $100 Million Non-Dilutive Financing with Abingworth

Retrieved on: 
Monday, August 2, 2021

NEWARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced a $100 million non-dilutive financing transaction with Abingworth to fund the Phase 3 development program for seladelpar in primary biliary cholangitis (PBC), including the Phase 3 RESPONSE clinical trial.

Key Points: 
  • Under the terms of the transaction, CymaBay will receive up to $100 million of seladelpar development costs, of which $75 million will be received in three installments over approximately six months.
  • CymaBay has an option to receive a further $25 million within approximately two months of the completion of enrollment of CymaBays Phase 3 RESPONSE clinical trial.
  • In exchange, CymaBay will make fixed payments spread over a six-year period based on regulatory approval in the U.S. or the E.U.
  • CymaBay has the ability to accelerate payment at a reduced amount upon regulatory approval and in the event of a change of control of CymaBay.

Lightbeam Health Solutions Partners with Surescripts to Promote Medication Adherence Across Populations

Retrieved on: 
Monday, August 2, 2021

Lightbeam Health Solutions, the leader in end-to-end population health management solutions and services, announces a new partnership with Surescripts, a nationwide health information network.

Key Points: 
  • Lightbeam Health Solutions, the leader in end-to-end population health management solutions and services, announces a new partnership with Surescripts, a nationwide health information network.
  • The Surescripts Medication History for Populations service will be available to Lightbeam clients through the partnership, adding valuable insights on top of the robust analytics already available within the Lightbeam platform.
  • Surescripts Medication History for Populations includes a newly launched patient notifications feature that provides real-time medication adherence alerts, including the ability to inform care teams when patients do not pick up prescribed medications.
  • Medication adherence is the single biggest issue around patient compliance, said Kent Locklear, MD, MBA, Chief Medical Officer of Lightbeam.

Sensyne grows medical research dataset to 60 million patients

Retrieved on: 
Monday, August 2, 2021

Between December 2020 and July 2021 Phesi grew its clinical research and clinical trial dataset from 13 million to 42 million patients through a concerted effort in acquiring and structuring data registries of de-identified data.

Key Points: 
  • Between December 2020 and July 2021 Phesi grew its clinical research and clinical trial dataset from 13 million to 42 million patients through a concerted effort in acquiring and structuring data registries of de-identified data.
  • At the same time, Sensyne, through its unique ethical Strategic Research Agreement (SRA) model that partners with healthcare systems, grew its real world patient dataset from 6 million to over 18 million patients.
  • Sixty million patients is an important milestone in our journey to create the worlds best data resource for medical research.
  • The 42 million Phesi clinical research and clinical trial dataset does not form part of this 100 million target.

Procaps Group to Host Virtual Investor and Analyst Day on Thursday, August 19, 2021 at 10:00 a.m. Eastern Time

Retrieved on: 
Monday, August 2, 2021

If you have difficulty connecting with the conference call, please contact MZ Group at +1 (949) 491-8235.

Key Points: 
  • If you have difficulty connecting with the conference call, please contact MZ Group at +1 (949) 491-8235.
  • Procaps Group is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents.
  • Procaps has a direct presence in 13 countries in Latin America and has more than 5,000 collaborators working under a sustainable model.
  • Procaps develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements and high-potency clinical solutions.